Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus DIFLUPREDNATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus DIFLUPREDNATE.
ALA-CORT vs DIFLUPREDNATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Difluprednate is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory mediators.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
Topical: Apply thin film to affected area twice daily.
None Documented
None Documented
Clinical Note
moderateDifluprednate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Gatifloxacin."
Clinical Note
moderateDifluprednate + Rosoxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Rosoxacin."
Clinical Note
moderateDifluprednate + Levofloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life approximately 2–4 hours; clinically, duration of action may extend due to receptor binding.
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Primarily renal (65–75% as metabolites), with biliary/fecal excretion accounting for 15–25%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
Difluprednate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Difluprednate is combined with Trovafloxacin."